3 Value Stocks That Raise Our Doubts

The Reality of Value Investing

Value investing has been the strategy behind the success of legendary investors like Warren Buffett, David Einhorn, and Seth Klarman, who amassed their wealth by acquiring strong businesses at attractive prices. However, truly undervalued stocks are rare—many companies that seem inexpensive remain so due to underlying, persistent challenges.

Spotting Genuine Value vs. Value Traps

Distinguishing between authentic bargains and so-called value traps can be difficult, even for seasoned investors. That’s why StockStory exists: to help you identify outstanding businesses. Below, we highlight three value stocks with weak fundamentals and suggest better alternatives to consider.

RingCentral (RNG)

Forward Price-to-Sales Ratio: 1.3x

RingCentral (NYSE:RNG) delivers AI-powered cloud communication and collaboration tools through its proprietary Message Video Phone (MVP) platform, enabling organizations to connect via voice, video, messaging, and contact center solutions.

Reasons to Avoid RNG:

• Customer interest has been lackluster, with average billings growing just 3.8% over the past year.
• Projected sales growth of 4.5% for the coming year signals a slowdown compared to its previous two-year pace.
• Intense competition forces the company to ramp up sales and marketing spending, often with limited returns.

Currently, RingCentral trades at $38.96 per share, reflecting a 1.3x forward price-to-sales ratio.

Fortune Brands (FBIN)

Forward Price-to-Earnings Ratio: 14.5x

Fortune Brands (NYSE:FBIN) serves both residential and commercial markets with a range of products, including plumbing, security, and outdoor living solutions.

Why FBIN May Not Be the Best Choice:

• Organic revenue growth has lagged expectations over the last two years, suggesting the need for improvements in products, pricing, or sales strategy.
• Operational efficiency has declined, with operating margins dropping by 9.8 percentage points over five years.
• Despite revenue increases, earnings per share have decreased by 8.9% annually over the past five years, indicating that new sales have been less profitable.

Fortune Brands is priced at $48.09 per share, equating to a 14.5x forward P/E ratio.

Amneal Pharmaceuticals (AMRX)

Forward Price-to-Earnings Ratio: 13.8x

Established in 2002, Amneal Pharmaceuticals (NASDAQ:AMRX) has become a major U.S. producer of generic drugs, manufacturing and distributing generic medications, specialty branded products, biosimilars, and injectables for the healthcare sector.

Concerns About AMRX:

• Forecasted sales growth of just 2.1% over the next year points to a slowdown compared to its recent two-year trend.
• Operating expenses have risen as a share of revenue over the past five years, with adjusted operating margins declining by 1 percentage point.
• Returns on capital have been below average, indicating management has struggled to identify high-return investment opportunities.

Amneal’s share price of $13.29 corresponds to a 13.8x forward P/E ratio.

Resilient Stocks for Any Market Environment

Don’t Miss Out: This Week’s Top 6 Stock Picks

In today’s rapidly shifting market, quality stocks are quickly separating themselves from overpriced ones. With AI disrupting entire industries overnight, simply having a list of good companies isn’t enough.

Our AI-driven platform identified Palantir before its 1,662% surge, AppLovin before its 753% rally, and Nvidia ahead of its 1,178% climb. Each week, it highlights six new stocks that meet these rigorous standards.

Our 2020 selections included now-household names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which delivered a 351% five-year return.